EBITDA: Income before interest, taxes, depreciation and amortization.
ENDRA Life Sciences Inc. (NDRA) had EBITDA of $-5.61M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.03M |
|
-- |
|
-- |
|
$5.76M |
|
$-5.76M |
|
$-1.26M |
|
$-7.03M |
|
$-7.03M |
|
$-7.03M |
|
$-7.03M |
|
$-7.03M |
|
$-7.03M |
|
$-5.76M |
|
|
EBITDA |
$-5.61M |
0.79M |
|
0.79M |
|
$-8.93 |
|
$-8.93 |
|
| Balance Sheet Financials | |
$0.97M |
|
$0.04M |
|
$2.89M |
|
$3.85M |
|
$0.75M |
|
-- |
|
$0.84M |
|
$1.59M |
|
$2.26M |
|
$2.26M |
|
$2.26M |
|
1.18M |
|
| Cash Flow Statement Financials | |
$-5.18M |
|
$-3.02M |
|
$5.73M |
|
$3.23M |
|
$0.76M |
|
$-2.47M |
|
$0.33M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.29 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.20M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-310.93% |
|
-310.93% |
|
-182.35% |
|
-310.93% |
|
$1.92 |
|
$-10.42 |
|
$-6.59 |
|